Farther Finance Advisors LLC Makes New Investment in Verona Pharma PLC American Depositary Share $VRNA

Farther Finance Advisors LLC bought a new stake in shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,000 shares of the company’s stock, valued at approximately $95,000.

Several other large investors have also recently modified their holdings of VRNA. NBC Securities Inc. bought a new position in shares of Verona Pharma PLC American Depositary Share during the 1st quarter valued at approximately $34,000. Geneos Wealth Management Inc. boosted its holdings in Verona Pharma PLC American Depositary Share by 44.2% during the 1st quarter. Geneos Wealth Management Inc. now owns 630 shares of the company’s stock valued at $40,000 after acquiring an additional 193 shares during the period. Acadian Asset Management LLC purchased a new position in Verona Pharma PLC American Depositary Share during the 1st quarter valued at $48,000. NewEdge Advisors LLC purchased a new position in Verona Pharma PLC American Depositary Share during the 1st quarter valued at $58,000. Finally, Advisors Preferred LLC boosted its holdings in Verona Pharma PLC American Depositary Share by 65.4% during the 1st quarter. Advisors Preferred LLC now owns 1,599 shares of the company’s stock valued at $94,000 after acquiring an additional 632 shares during the period. Institutional investors own 85.88% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Zacks Research upgraded Verona Pharma PLC American Depositary Share to a “hold” rating in a report on Friday, August 8th. Truist Financial cut Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 9th. Wolfe Research cut Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 10th. Piper Sandler cut Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 10th. Finally, Cantor Fitzgerald upped their target price on Verona Pharma PLC American Depositary Share from $90.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday, June 11th. Two investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $109.00.

Verona Pharma PLC American Depositary Share Stock Down 0.0%

Shares of VRNA opened at $106.79 on Friday. Verona Pharma PLC American Depositary Share has a 52 week low of $30.76 and a 52 week high of $106.86. The company has a quick ratio of 10.54, a current ratio of 10.71 and a debt-to-equity ratio of 0.87. The company has a market capitalization of $9.20 billion, a price-to-earnings ratio of -107.87 and a beta of 0.05. The stock’s 50-day moving average price is $105.91 and its 200-day moving average price is $87.83.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last issued its earnings results on Wednesday, August 6th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.14. Verona Pharma PLC American Depositary Share had a negative return on equity of 21.12% and a negative net margin of 36.62%.The firm had revenue of $103.14 million for the quarter, compared to the consensus estimate of $90.41 million. On average, sell-side analysts predict that Verona Pharma PLC American Depositary Share will post -1.95 EPS for the current year.

Insider Transactions at Verona Pharma PLC American Depositary Share

In other news, Director Vikas Sinha sold 4,328 shares of the company’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $13.14, for a total value of $56,869.92. Following the sale, the director owned 94,112 shares in the company, valued at $1,236,631.68. This represents a 4.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mahendra Shah sold 3,608 shares of the company’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $13.14, for a total value of $47,409.12. Following the completion of the sale, the director owned 93,472 shares in the company, valued at $1,228,222.08. The trade was a 3.72% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 540,584 shares of company stock valued at $7,103,274. 4.80% of the stock is owned by insiders.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.